News and Treatment Updates

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Dr. Valeria Santini gives overview of SOHO 2026 MDS session 

Original Publication Date
Article Source
External Web Content
Valeria Santini, MD, discusses advances in the treatment of myelodysplastic syndromes, including new therapeutic options for patients with lower-risk disease. “We do not only want to improve the quality of life, but also prolong survival,” Dr. Santini said. In addition to…

How Interferon Changes Cancerous Blood Stem Cells

Original Publication Date
Article Source
External Web Content
The biologic drug interferon-alpha can benefit patients with blood cancers called myeloproliferative neoplasms by forcing mutant blood stem cells to become shorter-lived white blood cells, according to a study by Weill Cornell Medicine investigators. Because the broad activity of…

Type 1 interferon perturbates clonal competition by reshaping human blood development

Original Publication Date
Article Source
External Web Content
Abstract Inflammation accelerates evolutionary dynamics of hematopoietic stem cells (HSCs) in clonal hematopoiesis and myeloid neoplasms. We studied HSCs, progenitors and immune cells from patients with myeloproliferative neoplasms at baseline and following interferon-α (IFNα)…

Ofirnoflast Offers Hope to Patients With ESA-Refractory LR-MDS

Original Publication Date
Article Source
External Web Content
Patients with erythropoiesis-stimulating agent (ESA)-refractory lower-risk myelodysplastic syndrome (LR-MDS) continued to benefit from the first-in-class allosteric NEK7/NLRP3 inhibitor ofirnoflast, according to results from a phase 2 study. With its favorable safety profile…

Acute myeloid leukemia cell therapy by combining MR1-modulating drugs and MR1 T cells   

Original Publication Date
Article Source
External Web Content
Abstract MR1-restricted T (MR1T) cells are a subset of unconventional T cells that recognize metabolite-derived antigens presented by the oligomorphic major histocompatibility complex class I–related molecule MR1. MR1T cells express a polyclonal T-cell receptor repertoire, can…

Infection risk in myelodysplastic syndromes is dynamic and immune driven   

Original Publication Date
Article Source
External Web Content
Key Points Infection risk in MDS is dynamic and biologically driven, influenced by neutropenia, therapy and immune reserve Treatment with azacitidine increases infection risk, with most infections occurring in the first six cycles Infection is a major cause of morbidity and…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.

We Recommend

For Patients and Families